肿瘤药学2025，Vol.15Issue(4)：530-535,6.DOI:10.3969/j.issn.2095-1264.2025.04.13
派安普利单抗联合培美曲塞及顺铂治疗转移性或局部晚期NSCLC的疗效研究及PD-1/PD-L1通路的调控作用
Efficacy of penpulimab combined with pemetrexed and cisplatin in the treatment of metastatic or locally advanced NSCLC and its regulatory effect on the PD-1/PD-L1 pathway
摘要
Abstract
Objective To evaluate the efficacy of penpulimab combined with pemetrexed and cisplatin in the treatment of metastatic or locally advanced non-small cell lung cancer(NSCLC)and to explore its regulatory effect on the PD-1/PD-L1 pathway.Methods A total of 180 NSCLC patients admitted to our hospital between August 2021 and June 2022 were en-rolled and randomly assigned to either the observation group(n=90,penpulimab plus pemetrexed and cisplatin)or the con-trol group(n=90,pemetrexed and cisplatin).Treatment outcomes were analyzed,and the regulatory role on the PD-1/PD-L1 pathway was investigated.Results The disease control rate was significantly higher in the observation group than in the control group(72.22%vs.53.33%,χ2=6.871,P<0.05).Before treatment,there was no significant difference in KPS scores between the two groups(P>0.05).After treatment,KPS scores increased significantly in both groups(P<0.001),and were significantly higher in the observation group than in the control group(P<0.001).Pretreatment levels of tumor markers(CA125,CEA,NSE,CYFRA21-1)showed no significant difference between groups(P>0.05).After treatment,these levels decreased significantly in both groups(P<0.001),with the observation group showing significantly lower levels than the con-trol group(P<0.001).No significant difference was found in pretreatment levels of CD3+and CD4+T lymphocytes(P>0.05).But after treatment,the observation group exhibited significantly increased CD3+and CD4+T lymphocyte levels,which were higher than those in the control group(P<0.001).There was no significant difference in the incidence of toxic side effects between the two groups after treatment(P>0.05).Pretreatment levels of soluble PD-1(sPD-1)and soluble PD-L1(sPD-L1)were comparable between groups(P>0.05).After treatment,these levels decreased significantly in both groups(P<0.001),with the observation group showing significantly lower levels than the control group(P<0.001).Conclu-sion Penpulimab combined with pemetrexed and cisplatin demonstrates significant efficacy in treating metastatic or locally advanced NSCLC.It improves patients'quality of life and enhances immune function.The mechanism of action may in-volve specifically blocking the PD-1/PD-L1 pathway,thereby reducing tumor cell immune escape and promoting tumor cell apoptosis.关键词
派安普利单抗/培美曲塞/顺铂/NSCLC/疗效/PD-1/PD-L1通路Key words
Penpulimab/Pemetrexed/Cisplatin/NSCLC:Curative effect/PD-1/PD-L1 pathway分类
医药卫生引用本文复制引用
武永存,姜溪,梁艳,要雪品,霍俊杰..派安普利单抗联合培美曲塞及顺铂治疗转移性或局部晚期NSCLC的疗效研究及PD-1/PD-L1通路的调控作用[J].肿瘤药学,2025,15(4):530-535,6.基金项目
邢台市科技局重点研发计划项目(2021ZC172). （2021ZC172）
